N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]Quinazoline-3-carboxamide
CAS: 802539-81-7
Rif. 3D-FT40655
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione |
Informazioni sul prodotto
Palbociclib is a drug that inhibits the activity of the cyclin-dependent kinase inhibitors (CDKIs) CDK4 and CDK6. It prevents their phosphorylation, which in turn prevents cells from progressing through the cell cycle. Palbociclib has been shown to be effective against a number of cancers including brain cancer, breast cancer, and ovarian cancer. Palbociclib is not active against non-malignant cells or cells that have already progressed through the cell cycle, such as thymoma cells. The LC-MS/MS method can be used to measure palbociclib levels in plasma and serum samples.